Indeed, high-dose IL-10 treatment in patients with endotoxemia or Crohn’s disease was associated with undesired pro-inflammatory effects by enhancing the production of other pro-inflammatory cytokines, such as IFN-γ (31). This evidence concerns the gene IL10 and serum lipopolysaccharide activity.